Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit

Study Overview
=================
Brief Summary
-----------------
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.

Detailed Description
-----------------
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness. Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs. Transient elastography is a useful tool validated for early diagnosis advanced chronic liver disease.It is non-invasive, fast, and gives immediate results. The aim of this study is to assess acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in psychiatric unit. Moreover, we will estimate de prevalence of advanced chronic liver diseases according to specific causes in psychiatry unit We hypothesize that the fact of offering psichiatric patents a non-invasive analysis of hepatic fibrosis will improve the detection of serious liver diseases and linkage to care.

Official Title
-----------------
Acceptability of Advanced Chronic Liver Disease Screening by Transient Elstography (Fibroscan ®) in Patients Hospitalised in Psychiatric Unit: a Single Center Prospective Study

Conditions
-----------------
Psychiatric Disorder, Psychiatric Hospitalization, Advanced Chronic Liver Disease, Liver Fibrosis

Intervention / Treatment
-----------------
* Diagnostic Test: non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria adults ≥18 years having a psychiatric condition and hospitalized in a psychiatry unit of CHU Montpellier , France patients who lack capacity of consent if legal representative consents involuntary psychiatric hospitalization, if consent is given Exclusion criteria lack of written consent Unable to understand nature and objective of the methodology Pregnant or breast feeding woman Not affiliated with a French social security

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Psychiatric patient<br>All patients having psychiatric disorders and hospitalised in a Psychiatry Unit of CHU Montpellier will have an non invasive evaluation of liver fibrosis after giving their consent | Diagnostic Test: non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)<br>* A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acceptability of non invasive assessement of liver fibrosis by Fibroscan in psychiatric patients | Number of patient who have agreed to do fibroscan screening among patient to whom it was offered. | At Inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of advanced liver disease in psychiatric patients | Number of patient who are diagnosed with advanced liver disease among patient to whom it was offered. | At inclusion | 
| prevalence of excessive alcohol or drug consumption in psychiatric patients | Number of patient with excessive alcohol/drug consumption | At inclusion | 
| prevalence of passed or active drug consumption (intraveinous, inhaled or sniffed) in psychiatric patients | Number of patient with excessive alcohol/drug consumption | At Inclusion | 
| prevalence of viral hepatitis in psychiatric patients | Number of patient diagnosed with viral hepatitis B, D, C | At Inclusion | 
| correlation between advanced chronic liver diseases and risk factors for liver diseases in psychiatric patients | Number of patients with advanced chronic liver disease among those having risk factors for chronic liver disease | 1 to 3 month after inclusion | 
| assessment of referral to medical care when advanced fibrosis was diagnosed, regardless of its etiology | Number of patients that have actually came to their medical appoint after advanced fibrosis diagnosis | 1 to 3 month after inclusion | 
| reason for refusal of non invasive evaluation of chronic liver disease | rate of reasons of refusal according to reason of hospitalization, sector, duration of hospitalization, time spend in study explaination, patient reflection time | At Inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
psychiatric disorders, advanced liver disease, alcoholic liver diseases, viral hepatitis, transient elastography (Fibroscan ®)